Johnson & Johnson Innovative Medicine company-sponsored congress materials which have been accepted for congress presentation at European Lung Cancer Conference

Preventing Moderate to Severe Dermatologic Adverse Events in First-line EGFR-mutant Advanced NSCLC Treated with Amivantamab Plus Lazertinib - Early Success of the COCOON Trial

Tremfya Dossier Update- docked

Rebranding

Submit your medical inquiry

Contact J&J Medical Connect for your medical inquiries


This page was last modified on

Additional contact #{index}

janssenscience

Congress Materials

Payer

oncology

preventing-moderate-to-severe-dermatologic-video

Whitelist Modal

Preventing Moderate to Severe Dermatologic Adverse Events in First-line EGFR-mutant Advanced NSCLC Treated with Amivantamab Plus Lazertinib - Early Success of the COCOON Trial

Medical inquiries